Search for: "Eli Lilly & Co."
Results 341 - 360
of 1,008
Sorted by Relevance
|
Sort by Date
18 Mar 2015, 7:00 am
Feb. 26, 2015), defendant Eli Lilly & Co. moved for summary judgment in a Byetta pancreatitis case, arguing that, under the “learned intermediary” doctrine, it was entitled to summary judgment on plaintiff’s claims that Byetta’s pancreatitis warnings were inadequate.Plaintiff cross-moved for summary adjudication, arguing that manufacturer’s duty to warn ran to the plaintiff because, pursuant to 21 C.F.R. [read post]
4 Jun 2010, 3:36 pm
Eli Lilly & Co., 598 F.3d 1336 (Fed. [read post]
6 Sep 2012, 11:29 am
Eli Lilly & Co. v. [read post]
12 Jan 2023, 4:23 pm
Aug. 31, 2016) (issuing letter of request where witness was located in Italy and possessed evidence that was relevant and unlikely to be duplicative); Eli Lilly & Co. v. [read post]
27 Feb 2009, 9:48 am
Kaul appears to be the phone calls from the Eli Lilly & Co. representatives. [read post]
17 Apr 2013, 6:12 am
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
29 Mar 2010, 4:34 pm
Eli Lilly and Co., Fed. [read post]
5 Jul 2015, 4:18 am
Furthermore, the previous week the England and Wales Court of Appeal issued a decision in Actavis UK Ltd & Ors v Eli Lilly & Company [2015] EWCA Civ 555, which also involved Swiss-type claims.It is interesting to compare the two decisions, particularly because, in my view, the UK court managed to completely undermine the European prohibition on patents for methods of medical treatment and must surely, therefore, be wrong! [read post]
18 Jan 2013, 7:28 am
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
14 Oct 2013, 11:33 am
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
7 Oct 2013, 6:02 am
Eli Lilly and Co., 119 F.3d 1559, 1566 (Fed. [read post]
17 Jul 2011, 9:55 am
There are two appeals in the Supreme Court beginning with Human Genome Sciences Inc v Eli Lilly and Company to be heard on Monday 18 to Wednesday 20 July 2011 by Lords Hope, Walker, Neuberger, Collins and Clarke. [read post]
1 Jul 2010, 5:20 am
Image via WikipediaThe FDA launched probes into possible risks from an Eli Lilly and Co (LLY.N) bloodthinner, a Sanofi-Aventis heart drug and other medicines.The FDA released its quarterly list of early investigations into health problems reported with various drugs on Wednesday.On the list, the agency said it was probing cases of thrombotic thrombocytopenic purpura (TTP) in patients treated with Effient, a blood thinner from Lilly and Daiichi Sankyo. [read post]
7 Jan 2010, 5:52 am
Tom Lamb and the Drug Injury Watch have a good article on the selective information given by Amylin Pharmaceuticals about their diabetes drug Byetta (co-marketed with Eli Lilly) to the media and their investors in October, 2009. [read post]
21 Aug 2015, 1:33 pm
Eli Lilly & Co., 2015 U.S. [read post]
27 Oct 2015, 11:41 am
Eli Lilly, 2015 U.S. [read post]
21 Feb 2006, 10:13 pm
" Takeda claimed in its September, 2003, and March, 2004, filings that the defendant generic drug companies were infringing a patent that Judge Cote called "remarkable" in her opinion, and the joint defendants claimed that Takeda misrepresented its list of compounds disclosed to the USPTO during prosecution, and that this patent, covering the Type-2 diabetes drug ACTOS ® (co-marketed by Takeda and Indianapolis based Eli Lilly & Company), was invalid… [read post]
3 Jun 2013, 7:49 pm
Eli Lilly and Company (Lilly) accounted for 10% of total revenue in 2011 and 18% of total revenue in 2012. [read post]
2 Dec 2005, 9:53 pm
A New Orleans law firm has challenged the legality of Eli Lilly and Co.'s $700 million settlement to pay liability claims over its top-selling drug Zyprexa. [read post]
11 Jan 2012, 9:44 pm
In 1998 Takeda entered into a marketing partnership with Eli Lilly and Co. to push Actos in the United States and obtain FDA approval. [read post]
